Over 90 Total Lots Up For Auction at One Location - WA 04/08

Novel theranostic reagent could enhance detection and therapy of prostate cancer

Press releases may be edited for formatting or style | November 27, 2019 Molecular Imaging

"To our knowledge, this is the first study to report in detail on the imaging findings of targeting STEAP1," said Carrasquillo. "Given the high SUV in tumor and localization of a large number of lesions, this reagent warrants further exploration as a companion diagnostic in patients undergoing STEAP1-directed therapy."

He continued, "The difference we observed in targeting PSMA with various radiotracers in patients with prostate cancer may possibly reflect differences related to the biology of STEAP1-versus PSMA-positive prostate cancer. Furthermore, as radiolabeled anti-PSMA antibodies were superseded by small molecules for PSMA imaging, there is potential to develop small molecules to target STEAP1 as well."

stats
DOTmed text ad

Your Centrifuge Specialty Store

Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576

stats

The authors of "Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody" include Jorge A. Carrasquillo, Neeta Pandit-Taskar and Steven M. Larson, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, Department of Radiology, Weill Cornell Medical Center, New York, New York, and Center for Targeted Radioimmunotherapy and Diagnosis, Ludwig Center for Cancer Immunotherapy, New York, New York; Stephen E. Fleming, Josef J. Fox, Sarah M. Cheal and Shutian Ruan, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; Bernard M. Fine and Simon P. Williams, Genentech, South San Francisco, California; Joseph A. O'Donoghue and John L. Humm, Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; Govind Ragupathi, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Serge K. Lyashchenko, Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York; Howard I. Scher, Daniel C. Danila and Michael J. Morris, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York and Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York; and Mithat Gönen, Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.


About The Journal of Nuclear Medicine
The Journal of Nuclear Medicine (JNM) is the world's leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 9 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field.

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging--precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

Back to HCB News

You Must Be Logged In To Post A Comment